Q&A: PureTech CEO Daphne Zohar talks biotech interests on Capitol Hill

As the year is nearing a close, lawmakers are still chipping away at spending bills and a long to-do list of health policy priorities that could come with some big changes for the biotech industry.

Endpoints News sat down with PureTech CEO and BIO board member Daphne Zohar to talk about the biggest issues facing biotech, what she urged lawmakers to prioritize during recent meetings on Capitol Hill with BIO board members, and why she thinks biotech needs to be legislated differently than pharma.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Survey: Americans want weight loss drugs despite high cost

Many Americans really want to lose weight — and a new poll shows nearly half of adults would be interested in taking a prescription drug

August 5, 2023

Some Health Workers See Double the Risk for Fatal Drug Overdoses

Certain healthcare workers including registered nurses (RNs) were at increased risk for fatal drug overdoses, a longitudinal study from 2008 to 2019 found. After adjustment

August 8, 2023

Study offers insights into who’s at risk for long COVID among immunocompromised patients

Early in the pandemic, clinicians noticed that certain immunocompromised patients were experiencing persistent SARS-CoV-2 infections, some lasting weeks to months at a time.

January 27, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.